Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Flavia Salvi, Stefano Luminari, Alessandra Tucci, Stefania Massidda, Anna Marina Liberati, Caterina Stelitano, Manuela Zanni, Alessandro Re, Riccardo Centurioni, Roberto Freilone, Gerardo Musuraca, Luca Nassi, Caterina Patti, Annalisa Arcari, Monica Tani, Alessandro Pulsoni, Vincenzo Pavone, Stefano Volpetti, Annalisa Peli, Andrea Evangelista, Michele Spina, Marco Ladetto & Francesco Merli. (2019) Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). Leukemia & Lymphoma 60:12, pages 2890-2898.
Read now
Read now
Sara Beygi, Santhosh Sadashiv, James B Reilly, Cyrus Khan & John Lister. (2018) Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era. Leukemia & Lymphoma 59:12, pages 2847-2861.
Read now
Read now
Nasimudeen R. Jabir, Khalid Anwar, Chelapram K. Firoz, Mohammad Oves, Mohammad Amjad Kamal & Shams Tabrez. (2018) An overview on the current status of cancer nanomedicines. Current Medical Research and Opinion 34:5, pages 911-921.
Read now
Read now
Emilio Iannitto, Stefano Luminari, Claudio Tripodo, Salvatrice Mancuso, Marina Cesaretti, Luigi Marcheselli, Francesco Merli, Caterina Stelitano, Angelo Michele Carella, Alberto Fragasso, Elisa Montechiarello, Giuseppina Ricciuti, Alessandro Pulsoni, Marco Paulli, Vito Franco & Massimo Federico. (2015) Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study. Leukemia & Lymphoma 56:12, pages 3281-3287.
Read now
Read now
Pier Luigi Zinzani, Massimo Federico, Stefano Oliva, Antonello Pinto, Luigi Rigacci, Giorgina Specchia, Alessandra Tucci & Umberto Vitolo. (2015) The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. Leukemia & Lymphoma 56:1, pages 12-25.
Read now
Read now
Paul M. Barr & Jonathan W. Friedberg. (2011) Getting to the heart of the problem in treating diffuse large B-cell lymphoma. Leukemia & Lymphoma 52:7, pages 1166-1167.
Read now
Read now
Articles from other publishers (11)
Mateusz Kciuk, Adrianna Gielecińska, Somdutt Mujwar, Damian Kołat, Żaneta Kałuzińska-Kołat, Ismail Celik & Renata Kontek. (2023) Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity. Cells 12:4, pages 659.
Crossref
Crossref
Kana Miyazaki. (2022) Management of elderly patients with malignant lymphoma. Japanese Journal of Clinical Oncology 52:7, pages 690-699.
Crossref
Crossref
Carlo Visco, Francesca Pregnolato, Isacco Ferrarini, Beatrice De Marco, Valentina Bonuomo, Eugenio Sbisà, Costanza Fraenza, Andrea Bernardelli, Ilaria Tanasi, Francesca Maria Quaglia & Mauro Krampera. (2021) Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis. Critical Reviews in Oncology/Hematology 163, pages 103377.
Crossref
Crossref
Alda Tavares & Ilídia Moreira. (2021) Diffuse large B-cell lymphoma in very elderly patients: Towards best tailored treatment – A systematic review. Critical Reviews in Oncology/Hematology 160, pages 103294.
Crossref
Crossref
Manish Vyas, Daniel A. Simbo, Mohd. Mursalin, Vijay Mishra, Roqia Bashary & Gopal L. Khatik. (2020) Drug Delivery Approaches for Doxorubicin in the Management of Cancers. Current Cancer Therapy Reviews 16:4, pages 320-331.
Crossref
Crossref
Stefano Luminari, Elda Viel, Andrés José Maria Ferreri, Francesco Zaja, Emanuela Chimienti, Gerardo Musuraca, Alessandra Tucci, Monica Balzarotti, Monica Tani, Francesca Salvi, Emanuela A. Pesce, Angela Ferrari, Anna M. Liberati, Antonio Spadea, Dario Marino, Maria Bruno-Ventre, Stefano Volpetti, Chiara Bottelli, Elena Ravaioli, Francesco Merli & Michele Spina. (2018) Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. Hematological Oncology 36:1, pages 68-75.
Crossref
Crossref
Huafei Li, Kun Guo, Cong Wu, Ling Shu, Shiwei Guo, Jing Hou, Naping Zhao, Lixin Wei, Xiaobo Man & Li Zhang. (2015) Controlled and Targeted Drug Delivery by a UV-responsive Liposome for Overcoming Chemo-resistance in Non-Hodgkin Lymphoma. Chemical Biology & Drug Design 86:4, pages 783-794.
Crossref
Crossref
Ines Wasle, Gabriele Gamerith, Florian Kocher, Patrizia Mondello, Thomas Jaeger, Alois Walder, Jutta Auberger, Thomas Melchardt, Werner Linkesch, Michael Fiegl & Michael Mian. (2014) Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. Annals of Hematology 94:4, pages 593-601.
Crossref
Crossref
Yang Ding, Yazhe Wang, Jianping Zhou, Xiaochen Gu, Wei Wang, Congyan Liu, Xiuli Bao, Cheng Wang, Yuanru Li & Qiang Zhang. (2014) Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis. Biomaterials 35:25, pages 7214-7227.
Crossref
Crossref
Chalid Assaf, Jürgen C. Becker, Marc Beyer, Antonio Cozzio, Edgar Dippel, Claus-Detlev Klemke, Peter Kurschat, Michael Weichenthal & Rudolf Stadler. (2013) Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin - Consensus of the lymphoma group of the Working Group Dermatologic Oncology. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 11:4, pages 338-347.
Crossref
Crossref
Ran Mo, Qiong Sun, Jingwei Xue, Nan Li, Wenyuan Li, Can Zhang & Qineng Ping. (2012) Multistage pH-Responsive Liposomes for Mitochondrial-Targeted Anticancer Drug Delivery. Advanced Materials 24:27, pages 3659-3665.
Crossref
Crossref